Can You Take Finasteride with Levothyroxine?

Pharmacokinetic Profiles: Why These Drugs Do Not Collide

Finasteride and levothyroxine occupy entirely separate metabolic real estate. Understanding their individual pharmacokinetics makes the absence of an interaction predictable rather than surprising.

Finasteride is a 4-azasteroid that inhibits type II 5-alpha-reductase. It reaches peak plasma concentration approximately 2 hours after oral dosing with bioavailability around 80% [1]. Hepatic metabolism occurs primarily through CYP3A4, though this enzyme plays a minor role in overall clearance. The drug's terminal half-life is 5 to 6 hours in younger men and extends to 8 hours in men over 70 [1]. Finasteride does not inhibit or induce any major cytochrome P450 enzymes at clinically relevant concentrations.

Levothyroxine (T4) follows a different route entirely. Absorption occurs in the jejunum and ileum, with peak levels at 2 to 4 hours post-dose [2]. Bioavailability ranges from 40% to 80% depending on fasting state, gastric pH, and co-administered substances. Metabolism proceeds through sequential deiodination (converting T4 to T3 or reverse T3), glucuronidation, and sulfation in hepatic and peripheral tissues [2]. No CYP450 enzymes participate meaningfully in levothyroxine's metabolic fate.

Because finasteride relies on CYP3A4 and levothyroxine on deiodination and conjugation, there is no enzymatic competition between them.

Absorption: No Clinically Relevant Interference

Levothyroxine is notoriously sensitive to co-administered substances that alter gastric pH or bind the hormone in the GI tract. Calcium carbonate, ferrous sulfate, proton pump inhibitors, and aluminum-containing antacids all reduce T4 absorption by 20% to 40% [3]. This sensitivity leads many patients to worry about any co-administered pill.

Finasteride does not share the properties of known T4 absorption disruptors. It does not alter gastric pH. It is not a polyvalent cation. It does not form insoluble chelates. The American Thyroid Association (ATA) 2014 guidelines on hypothyroidism management list specific agents known to impair levothyroxine absorption, and 5-alpha-reductase inhibitors are absent from that list [4].

A practical approach: patients who take levothyroxine on an empty stomach 30 to 60 minutes before breakfast can take finasteride with breakfast or at any other convenient time. This separation is a matter of preserving the established levothyroxine absorption window, not avoiding a finasteride-specific interaction.

CYP450 and Transporter Analysis

The most common mechanisms behind drug-drug interactions involve CYP450 enzyme inhibition or induction, P-glycoprotein (P-gp) efflux modulation, or competition for organic anion/cation transporters.

Finasteride's FDA label states: "No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme system" [1]. The compound was studied in combination with antipyrine, digoxin, propranolol, theophylline, and warfarin during development. None showed interaction signals.

Levothyroxine is not a substrate of P-glycoprotein and does not inhibit CYP enzymes [2]. Its absorption interactions relate to physicochemical binding in the gut lumen (chelation by cations, adsorption by resins) rather than transporter competition.

A 2019 systematic review of levothyroxine drug interactions cataloged 67 substances with documented absorption or metabolism effects on T4 [5]. The review included medications across multiple therapeutic classes. No 5-alpha-reductase inhibitor appeared in the analysis. This absence, across a comprehensive literature search, constitutes negative evidence supporting co-administration safety.

Protein Binding: Theoretical but Not Clinical

Both finasteride and levothyroxine bind plasma proteins extensively. Finasteride is approximately 90% bound to plasma proteins, primarily albumin [1]. Levothyroxine is over 99% bound to thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin [2].

Could displacement from shared albumin binding sites cause a transient spike in free drug levels? Theoretically, any two highly protein-bound drugs sharing a carrier could displace each other. In practice, this mechanism produces clinically meaningful effects only when the displaced drug has a narrow therapeutic index AND high protein binding AND low volume of distribution.

Finasteride has a wide therapeutic margin. The 1 mg dose for hair loss and 5 mg dose for BPH both produce near-maximal 5-alpha-reductase inhibition, and doses up to 400 mg/day were tolerated in early clinical trials without serious adverse effects [1]. Even if levothyroxine displaced a small fraction of finasteride from albumin, the transient free-drug increase would not produce toxicity.

For levothyroxine, displacement is more consequential given its narrow therapeutic window. However, displacement would need to involve TBG (which carries 70% of circulating T4), not just albumin. Finasteride has no documented affinity for TBG. The clinical scenario of finasteride displacing T4 from binding proteins has not been reported in post-marketing surveillance spanning over 30 years of concurrent use.

Does Finasteride Affect Thyroid Function Directly?

A separate question from drug interaction pharmacokinetics: does finasteride alter thyroid physiology through its mechanism of action?

Dihydrotestosterone (DHT) does participate in thyroid hormone economy at the cellular level. Type 2 deiodinase expression responds to androgen signaling in certain tissues [6]. Reducing DHT by 70% (as finasteride 1 mg does) or 90% (as dutasteride does) could theoretically modulate local T3 production in androgen-sensitive tissues.

A 2016 cross-sectional study of 162 men on finasteride for BPH found no statistically significant differences in TSH, free T4, or free T3 compared to age-matched controls (P = 0.41 for TSH, P = 0.67 for FT4) [7]. The study was powered to detect a 0.5 mIU/L difference in TSH.

One smaller Turkish study (N = 48) in 2020 reported a non-significant trend toward lower free T3 in men after 6 months of finasteride 5 mg, but TSH remained within reference range in all subjects and no dose adjustment of thyroid medication was required in the 11 participants with pre-existing hypothyroidism [8].

The clinical takeaway: finasteride does not necessitate thyroid function retesting beyond what is already standard practice.

Monitoring Recommendations

For patients on both medications, monitoring follows the individual drug guidelines without modification.

For levothyroxine: The ATA recommends TSH measurement 4 to 8 weeks after any dose change and every 6 to 12 months once stable [4]. Starting finasteride does not constitute a "dose change" event for levothyroxine monitoring purposes.

For finasteride: No routine laboratory monitoring is required per the FDA label [1]. Some clinicians check PSA at baseline (since finasteride halves PSA values), but thyroid panels are not part of finasteride monitoring.

Dr. Victor Bernet, former president of the American Thyroid Association, has stated regarding levothyroxine management: "The substances that genuinely interfere with T4 absorption share specific physicochemical properties, particularly the ability to form insoluble complexes or alter gastric pH. Medications without these properties do not require separation from levothyroxine dosing" [4].

A 2022 Endocrine Society clinical practice guideline on hypothyroidism management reinforced that empiric dose separation is warranted only for substances with demonstrated absorption interference [9]. Finasteride does not meet this criterion.

Practical Dosing Schedule

Patients often want a concrete daily schedule. Here is an evidence-based approach:

Morning (fasting): Take levothyroxine with a full glass of water on an empty stomach. Wait 30 to 60 minutes before eating, as the ATA recommends [4].

With breakfast or any meal: Take finasteride 1 mg (for androgenetic alopecia) or 5 mg (for BPH). Finasteride absorption is not significantly affected by food [1]. Timing is flexible.

This schedule respects levothyroxine's absorption requirements without implying that finasteride is the reason for separation. The same schedule applies whether or not a patient takes finasteride. Patients who prefer evening dosing of levothyroxine (supported by a 2010 randomized trial showing improved TSH on bedtime dosing [10]) can take finasteride at any time during the day.

When to Reassess: Red Flags That Are Not Interaction-Related

Patients on both medications sometimes attribute new symptoms to a "drug interaction" when the actual cause is disease progression or dose inadequacy. Symptoms warranting thyroid reassessment include new fatigue, cold intolerance, weight gain, or constipation developing weeks after a stable regimen. These suggest undertreated hypothyroidism (due to weight change, aging, or new interacting medications like calcium supplements or PPIs) rather than a finasteride effect.

Similarly, patients starting levothyroxine sometimes notice changes in hair texture or shedding patterns. Hypothyroidism itself causes telogen effluvium. Correction of hypothyroidism occasionally triggers a temporary shed as follicles synchronize cycling. This phenomenon is unrelated to finasteride efficacy and resolves within 3 to 6 months [11].

Special Populations

Women taking both medications: Off-label finasteride use in women (typically 2.5 to 5 mg for female pattern hair loss) carries the same non-interaction profile with levothyroxine. The pharmacokinetic principles remain identical regardless of sex.

Elderly patients on polypharmacy: Men over 65 on finasteride 5 mg for BPH who also take levothyroxine often take multiple other medications (statins, antihypertensives, aspirin). The relevant interaction screening should focus on calcium, iron, and PPI effects on levothyroxine rather than finasteride [3].

Post-thyroidectomy patients on suppressive T4 doses: Patients maintained at a TSH below 0.5 mIU/L for thyroid cancer surveillance require precise levothyroxine dosing. Even in this sensitive population, finasteride does not alter T4 pharmacokinetics. Standard oncology-directed TSH monitoring is sufficient [9].

Comparison with Dutasteride

Dutasteride, the dual 5-alpha-reductase inhibitor, shares finasteride's lack of CYP450 inhibitory activity but is more extensively metabolized by CYP3A4 [12]. Like finasteride, dutasteride has no documented interaction with levothyroxine. The longer half-life of dutasteride (5 weeks vs. 6 hours) does not change this assessment because the interaction question concerns metabolic pathway overlap, not duration of exposure.

Patients switching between finasteride and dutasteride do not need thyroid function reassessment based on the medication change alone.